MarketPulse

PSMA-targeted therapy

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix Pharmaceuticals to Showcase Next-Gen PSMA Cancer Therapy Portfolio

Telix Pharmaceuticals hosts webinar April 30 discussing next-gen PSMA cancer therapy pipeline, featuring OPTIMAL-PSMA2 trial data on TLX597-Tx candidate.
TLXclinical trialprostate cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Telix Pharma's TLX591-Tx Clears Phase 3 Safety Hurdle, Paves Path to Expansion

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.
TLXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

PYLARIFY Makes History as First Blockbuster Radiodiagnostic Amid PSMA Market Expansion

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.
NVSLNTHPET imagingPYLARIFY